ZIOPHARM Oncology, Inc. News
Why 2018 will be better for biotech deals than 2017
Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.
Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI
Here's what you need to know now for Monday, Jan. 22.
Immunotherapy stocks power higher on Celgene-Juno deal
Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.
More Immunotherapy Buyouts Likely After Kite Sale
More Immunotherapy Buyouts Likely After Kite Sale
Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views
Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.
Judgment Day; Good, Bad and Ugly: Doug Kass' Views
Doug Kass shares his thoughts on whether Judgment Day is here for the financials and discusses General Electric, Apple and Caterpillar.
Twitter, Netflix, MetLife: Doug Kass' Views
Doug Kass shares his thoughts on Twitter and talks about Sears.
Biotechs Among 5 Stocks Setting Up for Major Breakouts
Here's how to rake in the profits off some potential big breakouts.
Allergan, apple, facebook: doug kass' views
Doug Kass shares his thoughts on buying retail, and discusses why he's favoring the short side in a big way.
What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
TheStreet's biotech columnist offers his own report card on biotech stocks.
Breaking News
Dr. Doom Sees Plenty of Gloom: Roubini's Bearish Musings
He predicts a global economic and financial crisis, sparked by a debt bubble and accompanied by stagflation.
Carvana, the Amazon of Used Cars, Is Collapsing
The Amazon of used cars lost a third of its market value on Wednesday and payment deadlines loom.
Ford Gets a Big Win
The Dearborn, Mich., auto veteran is ramping up initiatives in the race to play a leading role in electric vehicles.